Strategic Moves Bolster Financial …
This article first appeared on GuruFocus. Total Revenue: $1.1 million for Q3 2025, compared to $0.1 million in Q3 2024. Total Operating Costs and Expenses: $6.5 million for Q3 2025, a decrease of 86% from $47.8 million in Q3 2024. R&D Expenses: $1.2 million for Q3 2025, down 94% from $20 million in Q3 2024. SG&A Expenses: $5.3 million for Q3 2025, a decrease of 43% from $9.4 million in Q3 2024. Net Loss from Continuing Operations: $13.1 million or $3.25 per share for Q3 2025, compared to $48.3 million or $12.01 per share in Q3 2024. Cash and Cash Equivalents: $121.1 million as of September 30, 2025. Cash Runway: Extended into 2028 following the sale of FibroGen China. FibroGen China Sale: Completed for approximately $220 million, including $135 million net cash held in Ch...










